DGAP-News: Medios AG
/ Key word(s): Preliminary Results
Medios AG: Strong growth in 2019 - Annual forecast slightly exceeded
Berlin, 6 February 2020 - Medios AG ('Medios'), one of the leading Specialty Pharma companies in Germany, has achieved strong growth in the 2019 financial year and slightly exceeded its annual forecast, which was significantly raised in September. According to preliminary calculations (IFRS), group sales in the period from January to December 2019 increased by 57.6 per cent year-on-year to EUR 516.8 million (previous year EUR 328 million). Group earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, rose by 51.5 per cent to EUR 17.8 million (previous year EUR 11.7 million). Group earnings before taxes (EBT), adjusted for extraordinary expenses*, climbed by 47.9 per cent to EUR 16.2 million (previous year EUR 11.0 million). According to its latest forecast, Medios had expected group sales of EUR 500 to 510 million, adjusted EBITDA* of EUR 17 to 18 million and adjusted EBT* of EUR 15 to 16 million.
Manfred Schneider, CEO of Medios AG: 'The 2019 financial year was our most successful in the history of Medios AG. We are convinced that the highly specialized independent local pharmacy has its justification and will further expand this position in the future with our help. This is one reason why we are increasingly winning specialized pharmacies as customers and are permanently expanding our partner network. Another reason is the expansion of our product range to include additional indication areas and increased investment in drug safety.'
Matthias Gärtner, CFO of Medios AG: 'In 2019, we have exceeded the sales mark of half a billion euros for the first time. In the current financial year, we want to continue to grow dynamically and benefit from the consolidation of the pharmaceutical market. Our goal is to become the market leader for Specialty Pharma solutions in Germany.'
The comprehensive consolidated financial statements of Medios AG will be published with the 2019 annual report in April 2020.
* EBITDA and EBT are each adjusted proportionately for extraordinary expenses for stock options in the amount of EUR 1.37 million (non-cash) for the 2019 financial year. EBT are also adjusted proportionately for extraordinary expenses for amortization of EUR 0.61 million (non-cash) on the customer base as a result of the acquisition of parts of MediosApotheke Anike Oleski e. Kfr. in the 2019 financial year.
About Medios AG
Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).
06.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||+49 30 232 566 - 800|
|Fax:||+49 30 232 566 - 801|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf|
|EQS News ID:||969443|
|End of News||DGAP News Service|